Department of Cardiology and Vascular Medicine, Faculty of Medical, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Auto-generated profile, based on publicly available information
Primasitha Maharany Harsoyo
Department of Cardiology and Vascular Medicine, Faculty of Medical, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Background Police officers are known for fieldwork shifts, psychological stress, and prolonged physical activity that are associated with cardiovascular disease (CVD). We aim to determine the differences in CVD risks factor and Atherogenic Index of Plasma (AIP) profiles as a predictor of cardiac events between police officers and civilians in a developing country as an evaluation and strategic preventive measure for CVD. Methods 978 participants were enrolled as subjects in this cross-sectional study. Data used were obtained during medical check-ups using complete physical and laboratory examinations including blood pressure, body mass index (BMI), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, fasting blood sugar, and AIP between 2019 and 2020 at Bhayangkara State Police Hospital Surabaya. Mann-Whitney U test was performed using IBM SPSS version 25. Results There are significant differences in systolic (p = 0.000) and diastolic blood pressure (p = 0.003), triglycerides (p = 0.000), LDL-C (p = 0.006), total cholesterol (p = 0.000), fasting blood glucose (p = 0.001), and the AIP (p = 0.000) between the police and civilian groups, with the latter showing a tendency of having higher rates. Conclusions CVD risk was found in both groups. Nevertheless, police officers have higher AIP and overall CVD risk compared to civilians, creating a necessity for aggressive CVD prevention strategies within the population.
1 July 2023 in Biomolecular and Health Science Journal
Introduction: Around 50% of patients with heart failure (HF) have an existing iron deficiency (ID), with or without anemia. With such a high prevalence, more research is underway to determine whether addressing ID can improve HF. Aims: This study aimed to critically evaluate the beneficial effects of intravenous iron administration for chronic HF. Methods: Studies were searched in Medline, Embase, and Cochrane for trials investigating the effect of iron supplementation on chronic HF patients. Outcomes of HF and all-cause hospitalizations, as well as cardiovascular-related and all-cause mortalities, were observed. We calculated the odds ratios (ORs) using fixed and random-effect models. The bias was evaluated by funnel plots and Egger's regression tests. Statistical analysis was conducted using RevMan (version 5.4.1). Results: Five studies with a total sample size of 1646 subjects were included in this meta-analysis and systematic review. Four studies reported the all-cause mortality of intravenous iron supplementation for HF. None of them provided evidence for the association between intravenous iron supplementation and all-cause mortality (OR = 0.75, 95% confidence interval [CI] 0.38–1.50, P = 0.42, I2= 0%, fixed effect). Four studies established that intravenous iron therapy significantly decreased hospitalization due to HF (OR = 0.56, 95% CI: 0.34–0.94, P = 0.03, I2= 53%, random effect). Conclusion: Iron supplementation does confer the benefit of iron supplementation in patients with chronic, stable HF with regard to HF hospitalization despite not showing significant associations in all-cause hospitalization, cardiovascular death, or all-cause mortality.
31 August 2021 in Indonesian Journal of Tropical and Infectious Disease
Since the fi rst report of pneumonia outbreak in Wuhan by the end of 2019, Coronavirus Disease 2019 (COVID-19) has become a global pandemic; causing millions of deaths globally and aff ecting the rest of worldwide population. The disease is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which enters hosts by inhabiting Angiotensin-Converting Enzyme-2 (ACE-2) receptors expressed in the endothelium layer of not only the respiratory tracts, but also various organs in the body. COVID-19 has been reported to trigger multiple cardiovascular manifestations. Since endothelial dysfunction plays an important role in cardiovascular events and the endothelium is heavily involved in COVID-19 pathophysiology, it is important to investigate their associations and previously established drug potencies to improve endothelial functions as possible treatment options for COVID-19. In this review, we summarize endothelial dysfunction biomarkers involved in COVID-19 and drugs that have shown potential endothelial protective properties to better understand the incidence of endothelial dysfunction in COVID-19 and its future treatment. We searched in PubMed, Wiley Online Library, EBSCO, ScienceDirect databases for literatures containing following keywords: “Endothelial dysfunction”, “COVID-19”, and “biomarkers”. Eligible publications were then assessed and studied to comprise our literature review. A total of 96 studies matched our criteria and provided scientifi c evidences for our review. Materials were then compiled into a review summarizing endothelial biomarkers involved in COVID-19 and potentially repurposed drugs targeting endothelium for COVID-19.Various endothelial dysfunction biomarkers were found to be elevated in COVID19 and is found to be related to its severity, such as adhesion molecules, selectins, PAI-1, and von Willebrand Factors. Multiple drugs targeting the endothelium are also potential and some are under investigation for COVID-19.
The expression of angiotensin-converting enzyme 2 (ACE2) in the adipose tissues of obese patients needs further study, as it may aid infection and serve as a viral reservoir. There has been controversy over whether to use ACE inhibitors to prevent coronavirus disease 2019 (COVID-19) severity. Perindopril, an ACE2 inhibitor, has been proposed; however, its relationship with COVID-19 has not yet been clear. The aim of this study was to investigate the effect of perindopril to reduce the expression of ACE2 and pro-inflammatory cytokine in adipocytes exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Enzymatic isolation of adipose tissues was performed from obese male donor patients aged 30–50 years, then exposed it with SARS-CoV-2 S1 spike protein. This study also included human recombinant ACE2 (hrsACE2) as a comparison to perindopril. The expression of ACE2 was evaluated using ELISA. Our data indicated that SARS-CoV-2 Spike protein exposure increased ACE2 expression significantly. Administration of perindopril decreased ACE2 expression (43.37 µg/mL) significantly compared to the positive group (80.31 µg/mL) (p<0.001). Perindopril administration also decreased IL-6 levels significantly compared to positive group(p<0.001). This study highlights that perindopril could reduce the ACE2 expression and pro-inflammatory cytokine levels in adipocytes exposed to SARS-CoV-2 S1 spike protein.
16 February 2022 in International Journal of Research Publications